



## Block Listing Return

March 1, 2022

RNS Number : 1158D

MaxCyte, Inc.

01 March 2022

MaxCyte, Inc.

("MaxCyte" or the "Company")

### Block Listing Return

**Gaithersburg, Maryland - 1 March 2022:** MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of <i>applicant</i> :		MaxCyte, Inc.			
Name of scheme:		MaxCyte Long Term Incentive Plan			
Period of return:	From:	1 September 2021	To:	28 February 2022	
Balance of unallotted securities under scheme(s) from previous return:		78,658 ordinary shares of common stock of \$0.01 each			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		13,000,000 ordinary shares of common stock of \$0.01 each			
<u>Less:</u> Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		901,574 ordinary shares of common stock of \$0.01 each			

Name of contact:	Amanda Murphy, Chief Financial Officer Ron Holtz, Chief Accounting Officer			
Telephone number of contact:	+1 301 944 1660			

For further information, please contact:

**MaxCyte Contacts:**  
*US IR Adviser*  
**Gilmartin Group**  
David Deuchler, CFA

+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

*Nominated Adviser and Joint Corporate Broker*  
Panmure Gordon  
Emma Earl / Freddy Crossley  
Corporate Broking  
Rupert Dearden

+44 (0)20 7886 2500

*UK IR Adviser*  
**Consilium Strategic Communications**  
Mary-Jane Elliott  
Chris Welsh

+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

### **About MaxCyte**

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@lseg.com](mailto:rs@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRFFFVLFITFIF